{
    "nctId": "NCT00005908",
    "briefTitle": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer",
    "officialTitle": "A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events",
    "eligibilityCriteria": "* INCLUSION CRITERIA:\n\nStage II or III breast cancer with a tumor size of greater than 2 cm. Patients with a previous biopsy are eligible provided adequate tumor tissue remains for biopsy in this study.\n\nAt least 18 years of age.\n\nAdequate hematopoietic function as defined by absolute neutrophil count greater than 1200/mm\\^3 and platelet count greater than 100,000/mm\\^3.\n\nAdequate renal function as defined by creatinine less than 1.6 mg/dL.\n\nAdequate hepatic function as defined by total (T.) bilirubin less than 1.4 mg/dL and serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times upper limit of normal\n\nZubrod Performance status 0-2.\n\nEXCLUSION CRITERIA:\n\nMedical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude chemotherapy administration. Patients may be evaluated by psychiatry or medical subspecialties as appropriate.\n\nPregnant or lactating women\n\nKnown bleeding disorders\n\nHypersensitivity to Tween 80 (Polysorbate)\n\nCardiac ejection fraction below normal limits, myocardial infarction within the past 12 months, or symptomatic arrhythmia requiring medical intervention.\n\nPrior chemotherapy or hormonal therapy for breast cancer. Patients treated with hormonal chemoprevention (tamoxifen or raloxifene) will be eligible.\n\nActive malignancy diagnosed within the last 5 years. (Cervical cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}